GCM
CRL icon

Geneva Capital Management’s Charles River Laboratories CRL Stock Holding History

Geneva Capital Management’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.53M Sell
11,174
-768
-6% -$137K 0.06% 102
2026
Q1 		$2.06M Sell
11,942
-214
-2% -$39.7K 0.04% 108
2025
Q4 		$2.42M Sell
12,156
-541
-4% -$98.1K 0.05% 111
2025
Q3 		$1.99M Sell
12,697
-368
-3% -$58.4K 0.03% 113
2025
Q2 		$1.98M Buy
13,065
+268
+2% +$35.7K 0.03% 113
2025
Q1 		$1.93M Buy
12,797
+7
+0.1% +$1.17K 0.04% 115
2024
Q4 		$2.36M Sell
12,790
-2,026
-14% -$390K 0.04% 116
2024
Q3 		$2.92M Sell
14,816
-418
-3% -$86.9K 0.05% 114
2024
Q2 		$3.15M Sell
15,234
-1,284
-8% -$291K 0.06% 112
2024
Q1 		$4.48M Buy
16,518
+244
+1% +$58.3K 0.08% 104
2023
Q4 		$3.85M Sell
16,274
-1,474
-8% -$290K 0.07% 103
2023
Q3 		$3.48M Sell
17,748
-641
-3% -$132K 0.07% 108
2023
Q2 		$3.87M Sell
18,389
-1,044
-5% -$208K 0.08% 103
2023
Q1 		$3.92M Sell
19,433
-617
-3% -$140K 0.08% 104
2022
Q4 		$4.37M Buy
20,050
+63
+0.3% +$13.8K 0.1% 102
2022
Q3 		$3.93M Sell
19,987
-2,189
-10% -$473K 0.09% 108
2022
Q2 		$4.75M Sell
22,176
-306
-1% -$74.8K 0.11% 103
2022
Q1 		$6.38M Buy
+22,482
New +$6.93M 0.12% 106

Other funds holding CRL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Geneva Capital Management's CRL Position: Q2 2026 in Review

Geneva Capital Management reduced its Charles River Laboratories (CRL) stake by 6.4% in Q2 2026, selling an estimated $137K and leaving 11,174 shares worth $2.53M. The position accounts for 0.06% of the portfolio, ranked #102.

Geneva Capital Management first reported a position in CRL in Q1 2022 and has held it in 18 quarters since. The position peaked at $6.38M in Q1 2022. 568 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • Geneva Capital Management held 11,174 shares of Charles River Laboratories worth $2.53M as of Q2 2026.
  • Geneva Capital Management sold 768 Charles River Laboratories shares in Q2 2026, an estimated $137K.
  • Charles River Laboratories made up 0.06% of Geneva Capital Management's portfolio in Q2 2026, its #102 holding.
  • Geneva Capital Management first reported a position in Charles River Laboratories in Q1 2022 and has held it in 18 quarters since.
  • Geneva Capital Management's Charles River Laboratories position peaked at $6.38M in Q1 2022.
  • 568 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Geneva Capital Management's 13F filing for Q2 2026, filed 6 Aug 2026.